No Data
No Data
百奧賽圖-B:2023年度報告
Biosetu-B (02315.HK) is expected to approach the break-even point in 2024 and plans to make further share purchases of no more than HK$10 million
Gelonghui announced on April 11 | Biosetu-B (02315.HK) announced that the company noticed unusual fluctuations in the stock price of the company's shares listed on the Hong Kong Stock Exchange Limited recently. The company hereby explains that there have been no major adverse events in its production and operation activities, and that all business lines have maintained steady growth and are progressing steadily in accordance with the established strategy. The company's board of directors and management team are confident in the company's development prospects and do not expect any significant adverse changes in the company's production and operation activities and financial situation. As disclosed in the overseas regulatory announcement on January 5, 2024, according to the company's careful calculations, the company is expected to reach 20
Baiosaitu-B (02315.HK) announced annual results: revenue reached 717 million yuan, up more than 34% year on year, and overseas market orders and revenue grew strongly
Baiosetu-B (02315.HK) announced its annual results. For the year ended December 31, 2023, the Group achieved operating income of approximately RMB 717 million, an increase of 34.3%; gross profit of approximately RMB 506 million, up 29.2% year on year, and gross profit margin of 70.6%, maintaining a high level. Annual losses narrowed sharply by about 36.4%% to RMB 383 million. During the reporting period, the results of continuing to expand overseas markets were remarkable, and overseas sales revenue continued to grow rapidly. Overseas market revenue surged 65.9% year over year to RMB 408 million, accounting for a share of total revenue
Understand Baiosetu-B (02315.HK)'s 2023 annual results in one picture
On the evening of March 26, Biosetu-B (02315.HK) announced the results for the year ended December 31, 2023. In 2023, the Group achieved revenue of RMB 717 million (same unit), an increase of 34% over the previous year. Among them, overseas revenue reached 408 million yuan, an increase of 66% over the previous year, and a gross profit margin of 71%, which is basically stable at a high level. Here's a picture to understand Baiosetu-B (02315.HK)'s 2023 results.
Baiosaitu-B (02315.HK): Achieved revenue of 717 million yuan in 2023, an increase of 34.3% year-on-year
On March 27, GLONGHUI | Biosetu-B (02315.HK) announced that for the year ended December 31, 2023, revenue increased by 34.3% year-on-year to approximately RMB 717 million. The increase was mainly due to increased revenue from model animal sales and antibody development. Gross profit (that is, revenue reduced sales costs) increased 29.2% year over year to approximately RMB 506 million. The increase in gross profit was mainly due to increased revenue from model animal sales and antibody development. The company's business model corresponds to the transfer of early antibody sequences produced by “thousands of antibodies” and joint development/authorized transfer/transfer development
BIOCYTOGEN-B: ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2023
No Data
meowmeow66 : I dont think moomoo can order this IPO. you can ask customer service to double check.